Prevention of type 2 diabetes in migrant populations from low- and middle-income countries living in high-income countries
Bennet L, Agyemang C
Diabetologia. Pub. online 7 Jun 2025.
Leggi
Associations of time in tight range, time in range, and glycated hemoglobin with albuminuria in type 1 diabetes: a cross-sectional study
Kim JY, Kim S, Park SH, et al.
Diabetes Res Clin Pract. 2025:112325.
Leggi
Post-authorisation safety study to assess the risk of urinary tract cancer in people with type 2 diabetes initiating empagliflozin: a multi-country European study
Schmedt N, Alhamdow A, Tskhvarashvili G, et al.
Diabetes Obes Metab. Pub. online 13 Jun 2025.
Leggi
Prevention of atrial fibrillation with SGLT2 inhibitors across the spectrum of cardiovascular disorders: a meta-analysis of randomised controlled trials
Fedele D, Casuso Alvarez M, Maida A, et al.
Eur Heart J Cardiovasc Pharmacother. 2025:pvaf040.
Leggi
Vegan diet, processed foods, and type 1 diabetes: a secondary analysis of a randomized clinical trial
Kahleova H, Himmelfarb J, Znayenko-Miller T, et al.
Nutr Metab Cardiovasc Dis. Pub. online 13 Jun 2025.
Leggi
Cellular adhesion molecules and adverse outcomes in chronic heart failure: findings from the DAPA-HF randomized clinical trial
McDowell K, Welsh P, Docherty KF, et al.
JAMA Cardiol. 2025:e251592.
Leggi
Screening accuracy of Single-Point Insulin Sensitivity Estimator (SPISE) for metabolic syndrome: a systematic review and meta-analysis
Azarboo A, Fallahtafti P, Jalali S, et al.
BMC Endocr Disord. 2025;25(1):142.
Leggi
Finerenone with empagliflozin in chronic kidney disease and type 2 diabetes
Agarwal R, Green JB, Heerspink HJL, et al.
N Engl J Med. Pub. online 5 Jun 2025.
Leggi
Once weekly IcoSema versus once weekly insulin icodec in type 2 diabetes management (COMBINE 1): an open label, multicentre, treat to target, randomised, phase 3a trial
Mathieu C, Giorgino F, Kim SG, et al.
Lancet Diabetes Endocrinol. Pub. online 4 Jun 2025.
Leggi
Once-weekly IcoSema versus multiple daily insulin injections in type 2 diabetes management (COMBINE 3): an open-label, multicentre, treat-to-target, non-inferiority, randomised, phase 3a trial
Billings LK, Andreozzi F, Frederiksen M, et al.
Lancet Diabetes Endocrinol. Pub. online 4 Jun 2025.
Leggi